Drug Trial Radar · NCT07028268
A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Jun 24, 2025
Primary completion
Dec 2025
Study completion May 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors
Conditions
- For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors
Interventions
SHR-2017、Denosumab placeboDrug
SHR-2017; high dose ;Denosumab placebo
SHR-2017、Denosumab placeboDrug
SHR-2017; low dose ;Denosumab placebo
Denosumab;SHR-2017 placeboDrug
Denosumab;SHR-2017 placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to pain reliefTime frame: randomization to 48 weeks after administration
- percentage of change in the bone turnover marker urine N-telopeptide corrected for urine creatinine (uNTx/Cr) from baseline to study week 13Time frame: randomization to 13 weeks after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.